Cargando…

A monoclonal antibody specifically reactive with Ewing's sarcoma.

We have developed a mouse monoclonal antibody 5C11 (IgG2a) against cell surface antigen of Ewing's sarcoma (ES). 5C11 specifically reacted with ESs but not with other small round cell tumours in childhood, i.e. neuroblastomas, primitive neuroectodermal tumours (PNETs), rhabdomyosarcomas and mal...

Descripción completa

Detalles Bibliográficos
Autores principales: Hara, S., Ishii, E., Tanaka, S., Yokoyama, J., Katsumata, K., Fujimoto, J., Hata, J.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1989
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2247257/
https://www.ncbi.nlm.nih.gov/pubmed/2605097
_version_ 1782150943147556864
author Hara, S.
Ishii, E.
Tanaka, S.
Yokoyama, J.
Katsumata, K.
Fujimoto, J.
Hata, J.
author_facet Hara, S.
Ishii, E.
Tanaka, S.
Yokoyama, J.
Katsumata, K.
Fujimoto, J.
Hata, J.
author_sort Hara, S.
collection PubMed
description We have developed a mouse monoclonal antibody 5C11 (IgG2a) against cell surface antigen of Ewing's sarcoma (ES). 5C11 specifically reacted with ESs but not with other small round cell tumours in childhood, i.e. neuroblastomas, primitive neuroectodermal tumours (PNETs), rhabdomyosarcomas and malignant lymphomas. 5C11 did not react with any other tumours in children except for hepatoblastomas. No reactivity has been identified in normal tissues with the exception of fetal hepatocytes. Immunoelectron microscopically, 5C11 reactive antigen was located on cell membrane of ES cells. Biochemically, 5C11 immunoprecipitated a cell surface protein having molecular weight of 81,000 Da. 5C11 is the first antibody which can clearly distinguish ES from neurogenic tumours, especially from PNETs which were recently reported to have common features to ESs regarding chromosal abnormality and proto-oncogene expression but show evident differentiation into neurogenic direction. The results strongly indicate the usefulness of 5C11 not only for diagnostic purpose when no specific marker is available but also for studying the histogenesis of ES. In addition, no reactivity in normal tissue implies its potential application as a therapeutic reagent when the management of ES patients is still a great problem in clinical field. IMAGES:
format Text
id pubmed-2247257
institution National Center for Biotechnology Information
language English
publishDate 1989
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-22472572009-09-10 A monoclonal antibody specifically reactive with Ewing's sarcoma. Hara, S. Ishii, E. Tanaka, S. Yokoyama, J. Katsumata, K. Fujimoto, J. Hata, J. Br J Cancer Research Article We have developed a mouse monoclonal antibody 5C11 (IgG2a) against cell surface antigen of Ewing's sarcoma (ES). 5C11 specifically reacted with ESs but not with other small round cell tumours in childhood, i.e. neuroblastomas, primitive neuroectodermal tumours (PNETs), rhabdomyosarcomas and malignant lymphomas. 5C11 did not react with any other tumours in children except for hepatoblastomas. No reactivity has been identified in normal tissues with the exception of fetal hepatocytes. Immunoelectron microscopically, 5C11 reactive antigen was located on cell membrane of ES cells. Biochemically, 5C11 immunoprecipitated a cell surface protein having molecular weight of 81,000 Da. 5C11 is the first antibody which can clearly distinguish ES from neurogenic tumours, especially from PNETs which were recently reported to have common features to ESs regarding chromosal abnormality and proto-oncogene expression but show evident differentiation into neurogenic direction. The results strongly indicate the usefulness of 5C11 not only for diagnostic purpose when no specific marker is available but also for studying the histogenesis of ES. In addition, no reactivity in normal tissue implies its potential application as a therapeutic reagent when the management of ES patients is still a great problem in clinical field. IMAGES: Nature Publishing Group 1989-12 /pmc/articles/PMC2247257/ /pubmed/2605097 Text en https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Research Article
Hara, S.
Ishii, E.
Tanaka, S.
Yokoyama, J.
Katsumata, K.
Fujimoto, J.
Hata, J.
A monoclonal antibody specifically reactive with Ewing's sarcoma.
title A monoclonal antibody specifically reactive with Ewing's sarcoma.
title_full A monoclonal antibody specifically reactive with Ewing's sarcoma.
title_fullStr A monoclonal antibody specifically reactive with Ewing's sarcoma.
title_full_unstemmed A monoclonal antibody specifically reactive with Ewing's sarcoma.
title_short A monoclonal antibody specifically reactive with Ewing's sarcoma.
title_sort monoclonal antibody specifically reactive with ewing's sarcoma.
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2247257/
https://www.ncbi.nlm.nih.gov/pubmed/2605097
work_keys_str_mv AT haras amonoclonalantibodyspecificallyreactivewithewingssarcoma
AT ishiie amonoclonalantibodyspecificallyreactivewithewingssarcoma
AT tanakas amonoclonalantibodyspecificallyreactivewithewingssarcoma
AT yokoyamaj amonoclonalantibodyspecificallyreactivewithewingssarcoma
AT katsumatak amonoclonalantibodyspecificallyreactivewithewingssarcoma
AT fujimotoj amonoclonalantibodyspecificallyreactivewithewingssarcoma
AT hataj amonoclonalantibodyspecificallyreactivewithewingssarcoma
AT haras monoclonalantibodyspecificallyreactivewithewingssarcoma
AT ishiie monoclonalantibodyspecificallyreactivewithewingssarcoma
AT tanakas monoclonalantibodyspecificallyreactivewithewingssarcoma
AT yokoyamaj monoclonalantibodyspecificallyreactivewithewingssarcoma
AT katsumatak monoclonalantibodyspecificallyreactivewithewingssarcoma
AT fujimotoj monoclonalantibodyspecificallyreactivewithewingssarcoma
AT hataj monoclonalantibodyspecificallyreactivewithewingssarcoma